Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7715839 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL1356717 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL5448 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL6654323 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL15952 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL213208 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL3690123 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL3834 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL10262394 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL15665811 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126876-A2 | ANTIMICROBIAL COMPOUNDS FOR ORAL CARE | CLARIANT INTERNATIONAL LTD (CH) | 2024-06-20 | — | — | WO | claimed |
| WO-2024069021-A2 | COMPOUNDS FOR USE AS WETTING AGENTS AND/OR DISPERSING AGENTS | CLARIANT INTERNATIONAL LTD (CH) | 2024-04-04 | — | — | WO | claimed |
| WO-2023247803-A2 | ANTIMICROBIAL COMBINATIONS | CLARIANT INTERNATIONAL LTD (CH) | 2023-12-28 | — | — | WO | claimed |
| WO-2023227802-A1 | ANTIMICROBIAL COMBINATIONS | CLARIANT INTERNATIONAL LTD (CH) | 2023-11-30 | — | — | WO | claimed |
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | claimed |
| CN-113825495-A | Non-injectable hydrogel formulations for smart release | 阿利维奥治疗学股份有限公司 | 2021-12-21 | — | — | CN | claimed |
| CN-113710331-A | Antimicrobial mixture | 西姆莱斯股份公司 | 2021-11-26 | — | — | CN | claimed |
| EP-3863602-A1 | NON-INJECTABLE HYDROGEL FORMULATIONS FOR SMART RELEASE | Alivio Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| US-20210196836-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | Alivio Therapeutics, Inc. | 2021-07-01 | — | — | US | claimed |
| CN-112996489-A | Sol-gel composition | 株式会社爱茉莉太平洋 | 2021-06-18 | — | — | CN | claimed |
| US-20080028977-A1 | Friction reduction composition and method | CRODA AMERICAS LLC | 2008-02-07 | — | — | US | claimed |
| EP-1667666-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRATE AND METHOD FOR THE PREPARATION THEREOF | ETHYPHARM (FR) | 2006-06-14 | — | — | EP | claimed |
| WO-2005032526-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRATE AND METHOD FOR THE PREPARATION THEREOF | ETHYPHARM (FR) | 2005-04-14 | — | — | WO | claimed |
| US-5512648-A | IMMUNOASSAY | Sparrow, James (US) | 1996-04-30 | — | — | US | claimed |
| US-5296572-A | Mixing unsaturated or alkenoylamine with dimethylacrylamide, crosslinker, water, adding emulsifier, adding organic phase, agitating, adding initiator, adjusting pH, adding promoter, polymerizing, isolating polyamide beads | Sparrow, James (US) | 1994-03-22 | — | — | US | claimed |
| US-5028675-A | Polyamide resin and method for preparation of reagents for immunodiagn ostic use | SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) | 1991-07-02 | — | — | US | claimed |
| US-4973638-A | DIMETHYLACRYLAMIDE, N-ACRYLYL DIAMINOALKANE, CROSSLINKER, AND EMULSIFIER | SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCHE (US) | 1990-11-27 | — | — | US | claimed |
| EP-0265501-A4 | POLYAMIDE RESIN AND METHOD FOR PREPARATION OF REAGENTS FOR IMMUNODIAGNOSTIC USE. | SOUTHWEST FOUND BIOMED RES (US) | 1988-11-09 | — | — | EP | claimed |
| EP-0265501-A1 | POLYAMIDE RESIN AND METHOD FOR PREPARATION OF REAGENTS FOR IMMUNODIAGNOSTIC USE | SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) | 1988-05-04 | — | — | EP | claimed |
| WO-1987006594-A1 | POLYAMIDE RESIN AND METHOD FOR PREPARATION OF REAGENTS FOR IMMUNODIAGNOSTIC USE | SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH (US) | 1987-11-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | PRKCA 2796/4885MAPT 2799/4885MAPK1 4859/4885 |
| US-20210196836-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | LTA, TMSB4X, TLN1 | PRKCA 4044/4885MAPT 1557/4885MAPK1 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.